ACS chemical neuroscience molecule spotlight on Valdoxen.
A new and novel non-SSRI potential treatment option for major depressive disorders is Valdoxen (agomelatine) which is currently in phase III clinical studies. Valdoxen is a norepinephrine disinhibitor (NNDI) and is also an antagonist of the 5-HT(2C) receptor.
Vanderbilt University Medical Center, Department of Pharmacology and Vanderbilt Program in Drug Discovery, Vanderbilt University, Nashville, TN, USA, 37232-6600.
Corey R
CR
Hopkins
D000081:Acetamides / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000928:Antidepressive Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D004311:Double-Blind Method; D004353:Drug Evaluation, Preclinical; D005221:Fatigue / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D009638:Norepinephrine / Q000819:agonists*; D016032:Randomized Controlled Trials as Topic; D044122:Receptor, Melatonin, MT1 / Q000819:agonists; D044123:Receptor, Melatonin, MT2 / Q000819:agonists; D044405:Receptor, Serotonin, 5-HT2C / Q000187:drug effects / Q000502:physiology; D058830:Serotonin 5-HT2 Receptor Antagonists; D009281:Naphthalenes
D000081:Acetamides; D000928:Antidepressive Agents; D009638:Norepinephrine; D044122:Receptor, Melatonin, MT1; D044123:Receptor, Melatonin, MT2; D044405:Receptor, Serotonin, 5-HT2C; D058830:Serotonin 5-HT2 Receptor Antagonists; C084711:agomelatine; D009281:Naphthalenes